DOW JONES27,960.80-1031.61 -3.56%
S&P 5003,225.89-111.86 -3.35%
NASDAQ9,221.28-355.31 -3.71%

Jefferies Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces $75 Price Target

Jefferies analyst Andrew Tsai initiates coverage on Relmada Therapeutics (NASDAQ:RLMD) with a Buy rating and a $75 price target.

Benzinga · 01/27/2020 11:22

Jefferies analyst Andrew Tsai initiates coverage on Relmada Therapeutics (NASDAQ:RLMD) with a Buy rating and a $75 price target.